GlassScriptPhysician profile
Ali U Farooq
NPI 1174907026
$5,215.25
in general payments reported to CMS, 2019-2025
27 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $129 · 2023: $3,187 · 2024: $264 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,360 · Travel and Lodging: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,360.30 |
| Travel and Lodging | $725.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,363.26 | 2023-2025 | Venaseal, Corevalve Evolut R, Hawkone |
| Shockwave Medical, INC | $860.37 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Terumo Medical Corporation | $375.32 | 2023 | Metacross Otw, Angio-Seal, Glidesheath Slender |
| Abbott Laboratories | $372.80 | 2023-2025 | Pressurewire, Dragonfly Opstar, Aveir |
| Boston Scientific Corporation | $260.35 | 2023-2024 | Rotablator Rotational Atherectomy System Console Kit, Mdu5 Plus Sterile Bag, Filterwire Ez |
| Cardiva Medical, INC. | $218.34 | 2023 | Cardiva Vascade 5f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Recor Medical INC | $202.37 | 2025 | Paradise Ultrasound Renal Denervation System |
| Bard Peripheral Vascular, INC. | $175.83 | 2023 | Venovo, Crosser Iq, Lifestream |
| Philips North America LLC | $156.93 | 2022-2023 | |
| Amgen INC. | $154.17 | 2023-2025 | Repatha, Repatha |
| Cook Medical LLC | $146.67 | 2023-2024 | Advance, Torcon Nb, Zilver Vena |
| Novartis Pharmaceuticals Corporation | $139.47 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.65 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $113.70 | 2023-2025 | Verquvo, Winrevair, Belsomra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $108.19 | 2023 | Lifevest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $88.44 | 2025 | Assure Wcd |
| Cagent Vascular INC | $76.07 | 2023 | Serrantor |
| E.R. Squibb & Sons, L.L.C. | $46.25 | 2023-2025 | Camzyos |
| Chiesi USA, INC. | $45.51 | 2023 | Kengreal |
| Ethicon INC. | $38.65 | 2025 | Monarch Platform |
| Surmodics, INC. | $28.20 | 2023 | Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Pounce Thrombectomy |
| Stryker Corporation | $24.85 | 2025 | Flowtriever |
| Asahi Intecc USA, INC. | $22.41 | 2023 | Asahi Ptca Guide Wire |
| Baxter Healthcare | $21.93 | 2025 | Hillrom - Monarch Airway Clearance System |
| Lantheus Medical Imaging, INC. | $21.75 | 2025 | |
| Novo Nordisk INC | $19.45 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $15.32 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.